These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26397126)

  • 21. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature.
    Kraemer M; Uekermann J; Wiltfang J; Kis B
    Clin Neuropharmacol; 2010 Jul; 33(4):204-6. PubMed ID: 20571380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cmap ADHD and comorbid aggression algorithm.
    Sharp BW
    J Am Acad Child Adolesc Psychiatry; 2007 Jan; 46(1):1. PubMed ID: 17195721
    [No Abstract]   [Full Text] [Related]  

  • 23. Pulmonary arterial hypertension in an adolescent treated with methylphenidate.
    Karaman MG; Atalay F; Tufan AE; Erdogan A
    J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):229-31. PubMed ID: 20578938
    [No Abstract]   [Full Text] [Related]  

  • 24. Report of a 14-Year-Old Boy Whose Testosterone Level Decreased After Starting on Methylphenidate.
    Akaltun İ
    J Child Adolesc Psychopharmacol; 2016 Mar; 26(2):181. PubMed ID: 26863036
    [No Abstract]   [Full Text] [Related]  

  • 25. Methylphenidate and hypertension.
    Prabhuswamy M; Srinath S; Girimaji S; Seshadri S
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):805-6. PubMed ID: 17201626
    [No Abstract]   [Full Text] [Related]  

  • 26. Visual fields in children with attention-deficit/hyperactivity disorder before and after treatment with stimulants.
    Ghanizadeh A
    Acta Ophthalmol; 2010 Mar; 88(2):e56. PubMed ID: 19508459
    [No Abstract]   [Full Text] [Related]  

  • 27. Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children: A viewpoint by Raul R. Silva.
    Silva RR
    Drugs; 2006; 66(8):1127-8; discussion 1128. PubMed ID: 16789798
    [No Abstract]   [Full Text] [Related]  

  • 28. Acute focal dystonic reaction after acute methylphenidate treatment in an adolescent patient.
    Tekin U; Soyata AZ; Oflaz S
    J Clin Psychopharmacol; 2015 Apr; 35(2):209-11. PubMed ID: 25607477
    [No Abstract]   [Full Text] [Related]  

  • 29. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Zarinara AR; Mohammadi MR; Hazrati N; Tabrizi M; Rezazadeh SA; Rezaie F; Akhondzadeh S
    Hum Psychopharmacol; 2010 Nov; 25(7-8):530-5. PubMed ID: 20860068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methylphenidate euphoria.
    Corrigall R; Ford T
    J Am Acad Child Adolesc Psychiatry; 1996 Nov; 35(11):1421. PubMed ID: 8936903
    [No Abstract]   [Full Text] [Related]  

  • 31. Supraventricular tachycardia in an adolescent with attention-deficit/hyperactivity disorder (ADHD).
    Hammerness PG; Wilens TE; Berul CI; Elkort MS
    J Am Acad Child Adolesc Psychiatry; 2008 Feb; 47(2):219-220. PubMed ID: 18216716
    [No Abstract]   [Full Text] [Related]  

  • 32. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder.
    Lurie S; O'Quinn A
    J Neuropsychiatry Clin Neurosci; 1991; 3(1):41-50. PubMed ID: 7580171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of stimulant medications for ADHD.
    Natl Bur Econ Res Bull Aging Health; 2014; (1):1-2. PubMed ID: 25141389
    [No Abstract]   [Full Text] [Related]  

  • 34. Methylphenidate in attention deficit hyperactivity disorder and bipolar disorder.
    Kummer A; Teixeira A
    Australas Psychiatry; 2008 Dec; 16(6):458-9. PubMed ID: 19034996
    [No Abstract]   [Full Text] [Related]  

  • 35. QuilliChew ER--extended-release chewable methylphenidate tablets.
    Med Lett Drugs Ther; 2016 May; 58(1495):68-9. PubMed ID: 27192619
    [No Abstract]   [Full Text] [Related]  

  • 36. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
    McGough JJ; McBurnett K; Bukstein O; Wilens TE; Greenhill L; Lerner M; Stein M
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):351-6. PubMed ID: 16768642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ADHD, methylphenidate and driving: does some legislation endanger public health?
    Verster JC; Cox DJ
    J Psychopharmacol; 2008 May; 22(3):227-9. PubMed ID: 18541623
    [No Abstract]   [Full Text] [Related]  

  • 38. [Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2006 Nov; 29(11):415-6. PubMed ID: 17131689
    [No Abstract]   [Full Text] [Related]  

  • 39. Methylphenidate and somatic hallucinations.
    Rashid J; Mitelman S
    J Am Acad Child Adolesc Psychiatry; 2007 Aug; 46(8):945-946. PubMed ID: 17667474
    [No Abstract]   [Full Text] [Related]  

  • 40. [Infantile psychosis secondary to methylphenidate].
    Fernández-Fernández MA; Rufo-Campos M; Mateos-Checa R; Muñoz-Cabello B; Madruga-Garrido M; Blanco-Martínez B
    Rev Neurol; 2011 Apr; 52(7):446-7. PubMed ID: 21425116
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.